Medicare Part D drug plans and Medicare Advantage Prescription Drug Plans (MA-PD) do not cover weight loss drugs
Adults 18+ with a BMI of 27 or higher, or 25+ with weight-related conditions Patients who have plateaued on a single-agonist GLP-1 and want to escalate under supervision People for whom faster onset and higher trial averages are clinically appropriate Personal or family history of medullary thyroid carcinoma or MEN 2 Pregnancy, breastfeeding, or planning pregnancy Active pancreatitis or untreated severe gastrointestinal disease Expected Timeline What to Expect Tirzepatide tends to act faster and reach further than single-agonist GLP-1s
These include: Medullary thyroid carcinoma (MTC): Retatrutide is contraindicated in individuals with personal or family history of thyroid cancer, such as medullary thyroid cancer or Multiple endocrine neoplasia syndrome type 2 (MEN 2), because this medication can increase the risk of thyroid C-cell tumors
The company also works with many of San Diegos nonprofits, museums, and cultural institutions
In 2025, biosimilars held approximately 20 percent average market share of the total biologics market in the US, up from less than 5 percent in 2020
